Increased serum levels of sCD40L were associated with rapidly progressive interstitial lung disease in idiopathic inflammatory myopathies

医学 内科学 间质性肺病 胃肠病学 凝血病 比例危险模型
作者
Wenting Lyu,Wanqing Zhou,Qingqing Xu,Xiaoqin Liu,Yin Liu,Yingwei Zhang,Yuying Qiu,Mei Huang,Min Cao,Yonglong Xiao,Hourong Cai,Jinghong Dai
出处
期刊:Clinical and Experimental Rheumatology 被引量:2
标识
DOI:10.55563/clinexprheumatol/a4a9ln
摘要

ObjectiveWhether coagulopathy exists in development of idiopathic inflammatory myopathies associated rapidly progressive interstitial lung disease (IIMs-RPILD) is unclear.In this study, we aimed to investigate soluble CD40 ligand and D-dimer levels in RPILD patients. Methods Patients with IIMs-ILD were enrolled and classified as RPILD and stable-ILD group. Clinical data, laboratory examinations including coagulation-associated parameters and the myositis antibodies status, chest high-resolutioncomputed tomography (HRCT) findings and treatment regimens were collected and serum levels of sCD40L were detected by ELISA.Univariable and adjusted multivariable cox regression were performed to identify risk factors for 6-month mortality, and further to select predictors for establishing predictive model for RPILD. ResultsEighty patients with IIMs-ILD were enrolled and 34 of them were diagnosed as RPILD while 46 as stable-ILD.Multivariable cox regression showed that albumin<32.4 g/L and sCD40L<1658.55pg/ml were independent risk factors of short-term mortality in RPILD.A SMAD model consisting of serum sCD40L>1054 pg/ml, anti-MDA5 positivity, albumin<32.4 g/L and D-dimer>0.865mg/L were generated.The odds for RPILD with SMAD score of 0, 1, 2, 3 and 4 were 0, 26.9%, 66.7%, 91.7% and 100%.The 6-month survival stratified by mild (SMAD score 0), moderate (SMAD score 1 and 2) and severe group (SMAD score 3 and 4) were 100%, 79.5% and 20%, respectively. Conclusion We established a predictive model for IIMs-RPILD, which provided a clue that coagulopathy might exist inIIMs-RPILD and could help to better treat patients with RPILD.This model awaits further validations.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
zho发布了新的文献求助30
2秒前
2秒前
ywang发布了新的文献求助10
2秒前
ZD小草完成签到 ,获得积分10
3秒前
健忘曼冬完成签到,获得积分10
4秒前
hkl1542发布了新的文献求助50
5秒前
6秒前
7秒前
KYN完成签到,获得积分10
8秒前
8秒前
桐桐应助叶未晞yi采纳,获得10
8秒前
8秒前
su发布了新的文献求助10
9秒前
123456789完成签到,获得积分10
11秒前
炙热的如柏完成签到,获得积分20
11秒前
12秒前
13秒前
HWei完成签到,获得积分10
13秒前
Ryan完成签到,获得积分10
13秒前
14秒前
Jzhang应助丙队长采纳,获得10
16秒前
17秒前
GXY发布了新的文献求助30
18秒前
Lucas应助专注秋尽采纳,获得10
18秒前
18秒前
754完成签到,获得积分10
18秒前
21秒前
学习猴发布了新的文献求助10
21秒前
充电宝应助炙热的如柏采纳,获得10
22秒前
所所应助qzaima采纳,获得10
22秒前
米兰达完成签到 ,获得积分0
23秒前
xg发布了新的文献求助10
25秒前
Loooong应助Ni采纳,获得10
26秒前
26秒前
WZ0904发布了新的文献求助10
26秒前
顾矜应助博ge采纳,获得10
28秒前
28秒前
Lotus发布了新的文献求助10
29秒前
30秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
Luis Lacasa - Sobre esto y aquello 700
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527990
求助须知:如何正确求助?哪些是违规求助? 3108173
关于积分的说明 9287913
捐赠科研通 2805882
什么是DOI,文献DOI怎么找? 1540119
邀请新用户注册赠送积分活动 716941
科研通“疑难数据库(出版商)”最低求助积分说明 709824